Nectar Lifesciences Limited (BOM:532649)
India · Delayed Price · Currency is INR 10.63
+0.37 (3.61%)
At close: Aug 21, 2026
Nectar Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 0.15 | - | 16,700 | 16,841 | 15,237 | 16,688 |
Other Revenue | 30.38 | - | 3.92 | 4.84 | 0.25 | 0.25 |
| 30.53 | - | 16,704 | 16,846 | 15,237 | 16,689 | |
Revenue Growth | -99.81% | - | -0.84% | 10.56% | -8.70% | 8.13% |
Cost of Revenue | 0.14 | - | 13,885 | 12,195 | 11,593 | 12,231 |
Gross Profit | 30.39 | - | 2,819 | 4,650 | 3,644 | 4,457 |
Selling, General & Admin | 29.56 | 19.12 | 985.1 | 865.6 | 796.01 | 763.07 |
Other Operating Expenses | 760.69 | 494.99 | 2,095 | 2,249 | 2,309 | 2,109 |
Operating Expenses | 793.91 | 517.54 | 3,704 | 3,722 | 3,696 | 3,441 |
Operating Income | -763.52 | -517.54 | -884.66 | 928.4 | -51.72 | 1,016 |
Interest Expense | -362.82 | -361.25 | -770.54 | -896.23 | -827.98 | -699.44 |
Interest & Investment Income | - | - | 14.89 | 123.9 | 17.26 | 18.84 |
Currency Exchange Gain (Loss) | - | - | 385.27 | 97.5 | 98.78 | 4.68 |
Other Non Operating Income (Expenses) | - | - | -360.51 | -72.68 | -65.67 | -93.34 |
EBT Excluding Unusual Items | -1,126 | -878.79 | -1,616 | 180.89 | -829.33 | 246.71 |
Gain (Loss) on Sale of Investments | - | - | 0.35 | 1.8 | 1.05 | 0.03 |
Gain (Loss) on Sale of Assets | - | - | -0.14 | - | 404.08 | 94.07 |
Pretax Income | -1,126 | -878.79 | -1,615 | 182.69 | -424.2 | 340.81 |
Income Tax Expense | -394.8 | -305.32 | -478.53 | 132.74 | -182.37 | 90.34 |
Earnings From Continuing Operations | -731.54 | -573.47 | -1,137 | 49.95 | -241.83 | 250.47 |
Earnings From Discontinued Operations | -1,719 | -2,355 | - | - | - | - |
Net Income | -2,451 | -2,929 | -1,137 | 49.95 | -241.83 | 250.47 |
Net Income to Common | -2,451 | -2,929 | -1,137 | 49.95 | -241.83 | 250.47 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 211 | 219 | 224 | 224 | 224 | 224 |
Shares Outstanding (Diluted) | 211 | 219 | 224 | 224 | 224 | 224 |
Shares Change | -5.35% | -2.54% | - | - | - | - |
EPS (Basic) | -11.60 | -13.40 | -5.07 | 0.22 | -1.08 | 1.12 |
EPS (Diluted) | -11.60 | -13.40 | -5.07 | 0.22 | -1.08 | 1.12 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -3,610 | 1,256 | 1,953 | 1,036 | 700.35 |
Free Cash Flow Per Share | - | -16.52 | 5.60 | 8.71 | 4.62 | 3.12 |
Gross Margin | 99.55% | - | 16.88% | 27.61% | 23.92% | 26.71% |
Operating Margin | -2501.21% | - | -5.30% | 5.51% | -0.34% | 6.09% |
Profit Margin | -8027.84% | - | -6.81% | 0.30% | -1.59% | 1.50% |
Free Cash Flow Margin | - | - | 7.52% | 11.59% | 6.80% | 4.20% |
EBITDA | -634.45 | -289.51 | -260.77 | 1,536 | 539.47 | 1,586 |
EBITDA Margin | - | - | -1.56% | 9.12% | 3.54% | 9.50% |
D&A For EBITDA | 129.07 | 228.03 | 623.89 | 607.18 | 591.19 | 569.68 |
EBIT | -763.52 | -517.54 | -884.66 | 928.4 | -51.72 | 1,016 |
EBIT Margin | - | - | -5.30% | 5.51% | -0.34% | 6.09% |
Effective Tax Rate | - | - | - | 72.66% | - | 26.51% |
Revenue as Reported | 123.44 | 92.91 | 16,750 | 16,987 | 15,668 | 16,802 |